IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

NCT00488839 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: IPX056 20 mg
DRUG: IPX056 40 mg
DRUG: Encapsulated Baclofen 20 mg
DRUG: Placebo Baclofen Tablet
DRUG: IPX056 10 mg
DRUG: IPX056 30 mg
DRUG: IPX056 35 mg
DRUG: Placebo IPX056 20 mg
DRUG: Placebo IPX056 40 mg

Sponsor

Impax Laboratories, LLC